Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
europe blog main
6
×
life sciences
6
×
national blog main
national top stories
boston blog main
clinical trials
europe top stories
fda
national
new york blog main
allergan
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
covid-19
gilead sciences
merck
novartis
sanofi
What
bio
roundup
acquisitions
ceo
daniel
debut
drug
fda
gilead
medicines
moves
o’day
sciences
treatment
week
abbvie’s
adults
ahead
alkermes
allergan
announced
antipsychotic
approved
benefits
biggest
biofourmis
black
bucks
build
buy
cancer
caveats
celebrate
chance
class
collabs
commonly
companies
company’s
continue
Language
unset
6
×
Current search:
abbvie
×
unset
×
" life sciences "
×
" europe blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines